Jefferies Starts Atara Biotherapeutics (ATRA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
November 12, 2014 6:36 AM ESTAtara Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($4.20), versus ($2.59) reported last year.
For earnings history and earnings-related data on Atara Biotherapeutics (ATRA) click here.
... MoreGoldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral
November 10, 2014 7:20 AM ESTGoldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.
Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More
